Clinical Policy: Siponimod (Mayzent)
Reference Number: CP.PHAR.427
Effective Date: 09.01.19
Last Review Date: 08.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Siponimod (Mayzent®) is a sphingosine 1-phosphate receptor modulator.

FDA Approved Indication(s)
Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Mayzent is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Multiple Sclerosis (must meet all):
      1. Diagnosis of one of the following (a, b, or c):
         a. Clinically isolated syndrome;
         b. Relapsing-remitting MS;
         c. Secondary progressive MS;
      2. Prescribed by or in consultation with a neurologist;
      3. Age ≥ 18 years;
      4. Documentation that member does not have a CYP2C9*3/*3 genotype (see Appendix D);
      5. Mayzent is not prescribed concurrently with other disease modifying therapies for MS (see Appendix D);
      6. Documentation of baseline number of relapses per year and expanded disability status scale (EDSS) score;
      7. Dose does not exceed 2 mg per day.
   Approval duration: 6 months

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.
II. Continued Therapy
   A. Multiple Sclerosis (must meet all):
      1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
      2. Member meets one of the following (a or b):
         a. If member has received < 1 year of total treatment: Member is responding positively to therapy;
         b. If member has received ≥ 1 year of total treatment: Member meets one of the following (i, ii, iii, or iv):
            i. Member has not had an increase in the number of relapses per year compared to baseline;
            ii. Member has not had ≥ 2 new MRI-detected lesions;
            iii. Member has not had an increase in EDSS score from baseline;
            iv. Medical justification supports that member is responding positively to therapy;
      3. Mayzent is not prescribed concurrently with other disease modifying therapies for MS (see Appendix D);
      4. If request is for a dose increase, new dose does not exceed 2 mg per day.
       Approval duration: first re-authorization: 6 months; second and subsequent re-authorizations: 12 months

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
       Approval duration: Duration of request or 6 months (whichever is less); or
      2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   EDSS: expanded disability status scale
   FDA: Food and Drug Administration
   MS: multiple sclerosis
   
   Appendix B: Therapeutic Alternatives
   Not applicable
Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Patients with a CYP2C9*3/*3 genotype
  - In the last 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
  - Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker

- Boxed warning(s): none reported

Appendix D: General Information

- Disease-modifying therapies for MS are: glatiramer acetate (Copaxone®, Glatopa®), interferon beta-1a (Avonex®, Rebif®), interferon beta-1b (Betaseron®, Extavia®), peginterferon beta-1a (Plegridy®), dimethyl fumarate (Tecfidera®), diroximel fumarate (Vumerity™), monomethyl fumarate (Bafiertam™), fingolimod (Gilenya™), teriflunomide (Aubagio®), alemtuzumab (Lemtrada®), mitoxantrone (Novantrone®), natalizumab (Tysabri®), ocrelizumab (Ocrevus™), siponimod (Mayzent®), cladribine (Mavenclad®), and ozanimod (Zeposia®).

- The CYP2C9 genotype has a significant impact on siponimod metabolism. Mayzent is contraindicated in patients homozygous for CYP2C9*3 (i.e., CYP2C9*3/*3 genotype), which is approximately 0.4%-0.5% of Caucasians and less in others, because of substantially elevated siponimod plasma levels. Mayzent dosage adjustment is recommended in patients with CYP2C9*1/*3 or *2/*3 genotype because of an increase in exposure to siponimod.

- The American Academy of Neurology 2018 MS guidelines recommend the use of Gilenya, Tysabri, and Lemtrada for patients with highly active MS. Definitions of highly active MS vary and can include measures of relapsing activity and MRI markers of disease activity, such as numbers of gadolinium-enhanced lesions.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>All patients:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 1 and 2: 0.25 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 3: 0.5 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 4: 0.75 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(\text{CYP2C9 genotypes *1/*1, *1/*2, or *2/*2:})</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 5: 1.25 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 6 and onward: 2 mg PO QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(\text{CYP2C9 genotypes *1/*3 or *2/*3:})</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 5 and onward: 1 mg PO QD</td>
<td></td>
</tr>
</tbody>
</table>

2 mg/day

VI. Product Availability

- Tablets: 0.25 mg, 2 mg
VII. References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>Policy created</th>
<th>Added Commercial and HIM line of business to policy, retire CP.CPA.341 and HIM.PA.SP37; removed redirections for clinically isolated syndrome and relapsing-remitting MS per SDC and prior clinical guidance.</th>
<th>Added requirements for documentation of baseline relapses/EDSS and objective measures of positive response upon re-authorization; modified continued approval duration to 6 months for the first re-authorization and 12 months for second/subsequent re-authorizations; references reviewed and updated.</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>05.14.19</td>
<td>08.19</td>
<td>01.15.20</td>
<td>05.27.20</td>
<td>05.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,
contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.